JHK Investments

JHK Biopharma is a biopharmaceutical company based in Shanghai, China, primarily focused on the development and commercialization of advanced drug delivery systems. The company operates as a strategic joint venture with South Korea's Daehwa Pharm, leveraging transdermal drug delivery and oral dissolving film technologies to address unmet needs in neurology and oncology. Its lead program is a rivastigmine transdermal patch for the treatment of Alzheimer's-related dementia, which has been submitted for regulatory approval in China. JHK Biopharma aims to bridge international pharmaceutical innovations with the rapidly expanding Chinese healthcare market through specialized manufacturing and clinical development partnerships.